![Bertram Köhler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bertram Köhler
Vorstandsvorsitzender bei DEUTSCHE EFFECTEN- UND WECHSEL-BETEILIGUNGSGESELLSCHAFT AG
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Joseph deBethizy | M | 75 |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 8 Jahre |
| Walter Wenninger | M | 86 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Marco Scheidler | M | 45 |
DEWB AG (Venture Capital)
 DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 18 Jahre |
| Aram Andrew Mangasarian | M | 55 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 15 Jahre |
| Susan Coles | F | 59 | 4 Jahre | |
| Jarl Ulf Birger Jungnelius | M | 74 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 8 Jahre |
| Maurizio PetitBon | M | 77 | 9 Jahre | |
| Olivier Litzka | M | 57 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Cornelis Alexander Izeboud | M | 54 | 5 Jahre | |
| Sven Klussmann | M | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | 28 Jahre |
| Henning Soltau | M | 59 | 8 Jahre | |
| Peter Johann | M | 68 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Denis Lucquin | M | 68 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | - |
| Rolf Ackermann | M | 57 | 8 Jahre | |
| Jürgen Kreis | M | - |
LemnaTec GmbH
 LemnaTec GmbH Medical SpecialtiesHealth Technology LemnaTec GmbH develops research platforms and analysis software for agricultural chemistry, plant cultivation, biotechnology, and pharmacy. It generates reproducible and scientifically sound images in light wavelengths. The firm develops also imaging, image analysis automatisation, and data handling modules. The company was founded by Dirk Vandenhirtz and Matthias Eberius in 1998 and is headquartered in Aachen, Germany. | - |
| Ewelina Staniuk | F | - | 7 Jahre | |
| Jörg Ohlsen | M | 70 | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Vergangene Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Falk Nuber | M | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 11 Jahre |
| Mirko Wäckerle | M | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 11 Jahre |
| Martine van Vugt | M | 72 | 2 Jahre | |
| Gregory Weaver | M | 69 | 1 Jahre | |
| Achim Plate | M | 66 | 2 Jahre | |
| Mark Andrews | M | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 10 Jahre |
| Marc Bauer | M | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 10 Jahre |
| Christiane Bednarek | F | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 12 Jahre |
| Jörg Gehler | M | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 4 Jahre |
| Gerhard Fettweis | M | 63 | - | |
| Hubert Birner | M | 58 | - | |
| Walter Blumenthal | M | 78 | 8 Jahre | |
| Mark Andrews | M | - |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | 5 Jahre |
| Thomas Kordick | M | 61 | - | |
| Matthias Baumann | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Deutschland | 32 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Provenance des relations
- Börse
- Insiders
- Bertram Köhler
- Persönliches Netzwerk
